Almac Group has received a renewal of its GMP/GDP certification following the successful regulatory inspection by the Health Sciences Authority (HSA) of its facility in Singapore.   

The organization’s Asia Pacific headquarters and clinical trial supply facility was first established in Singapore in 2015 and vastly expanded Almac’s range of unique solutions offered from within the region to further optimize the clinical supply chain for both global and regional studies in their customers’ own language and time zones. This accreditation was awarded after an on-site 3 day inspection held in June 2018 confirming Almac’s compliance with the HSA standards of safety, quality and efficacy across its various operations.

Almac has continued to invest in and strengthen its in-region capabilities which are a key part of its ongoing global expansion strategy to meet market and patient needs. As part of this strategy, the facility has seen a 40% uplift in business volume, which has led to the creation of further permanent jobs at the Singapore and Japanese facilities.